Axcelead is the first integrated drug discovery solutions provider in the pharmaceutical industry in Japan, having inherited the unique and comprehensive capabilities of drug discovery from Takeda Pharmaceutical Company Limited： “Experienced Scientists”, “Cutting-edge Technology Platform”, and “Huge Historical Drug Discovery Data”, and started its business in 2017.
Looking for a solution in terms of a specific research theme, stage or modality
Axcelead offers the optimum solution in line with your research themeClick here for details
Axcelead offers fully integrated drug discovery services from target discovery to IND enabling translational researchClick Here for Details
The new modalities support epoch-making discovery research including breakthroughs in regenerative medicine, nucleic acids and peptide drug discoveryClick Here for Details
Our highly experienced and expert staff will take care of your non-clinical development strategy and work to solve any problemsClick Here for Details
One-stop shop for human genome knock-in (KI) mouse/rat assessment services
For clients interested in out-licensing
Results of joint research with the University of Tokyo published in the international scientific journal “Nature Communications”
FRONTEO and Axcelead DDP Sign Master Collaboration Agreement for AI Drug Discovery Support Partnership
BIO-Europe: Meet us in Munich, Germany
HTS is a service to identify hit compounds with high probability in a short period of time.
We enable improvement of drug development efficiency and seamless translational research!
We offer an optimal package service for you to achieve your goal, such as IND application and out-licensing
Check out our latest scientific research, insights and passion for drug discovery.
Omics analysis, creating the future of drug discovery research ～Mechanism exploration with multilayer-omics analysis～
Ion channel drug discovery with leading-edge facilities and a strategic approach!～Drug discovery ability to overcome challenges～
Azusa Seki, Ryosuke Hibino, Mitsuru Hirano
Ceaselessly advancing integrated safety assessment of the cardiovascular system
Let’s explore the appeal of Axcelead Drug Discovery Partners’ hERG current assay!
～To be the best partner for cardiac toxicity assessment～
We enjoy the patronage of more than 100 facilities, including pharmaceutical companies, startups and academic institutions